Frontiers in Oncology (May 2023)

IL-22BP controls the progression of liver metastasis in colorectal cancer

  • Anastasios D. Giannou,
  • Anastasios D. Giannou,
  • Anastasios D. Giannou,
  • Anastasios D. Giannou,
  • Jan Kempski,
  • Jan Kempski,
  • Jan Kempski,
  • Tao Zhang,
  • Tao Zhang,
  • Jöran Lücke,
  • Jöran Lücke,
  • Jöran Lücke,
  • Ahmad Mustafa Shiri,
  • Ahmad Mustafa Shiri,
  • Dimitra E. Zazara,
  • Dimitra E. Zazara,
  • Ioannis Belios,
  • Andres Machicote,
  • Andres Machicote,
  • Philipp Seeger,
  • Theodora Agalioti,
  • Joseph Tintelnot,
  • Joseph Tintelnot,
  • Adrian Sagebiel,
  • Miriam Tomczak,
  • Miriam Tomczak,
  • Lennart Bauditz,
  • Lennart Bauditz,
  • Tanja Bedke,
  • Tanja Bedke,
  • Lorenz Kocheise,
  • Lorenz Kocheise,
  • Baris Mercanoglu,
  • Mohammad Fard-Aghaie,
  • Emmanouil Giorgakis,
  • Emmanouil Giorgakis,
  • Panagis M. Lykoudis,
  • Panagis M. Lykoudis,
  • Anastasia Pikouli,
  • Julia-Kristin Grass,
  • Ramez Wahib,
  • Jan Bardenhagen,
  • Benjamin Brunswig,
  • Asmus Heumann,
  • Tarik Ghadban,
  • Anna Duprée,
  • Michael Tachezy,
  • Nathaniel Melling,
  • Petra C. Arck,
  • Pablo Stringa,
  • Maria Virginia Gentilini,
  • Gabriel E. Gondolesi,
  • Ryosuke Nakano,
  • Angus W. Thomson,
  • Angus W. Thomson,
  • Daniel Perez,
  • Jun Li,
  • Oliver Mann,
  • Jakob R. Izbicki,
  • Nicola Gagliani,
  • Nicola Gagliani,
  • Ioannis C. Maroulis,
  • Samuel Huber,
  • Samuel Huber

DOI
https://doi.org/10.3389/fonc.2023.1170502
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundThe immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown.MethodsWe used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages.ResultsOur data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice.ConclusionsWe here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.

Keywords